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Background: The three Tiao-Bu Fei-Shen (Bufei Jianpi, Bufei Yishen, Yiqi Zishen) granules have been confirmed for
their beneficial clinical efficacy in chronic obstructive pulmonary disease (COPD) patients on reducing frequency
and duration of acute exacerbation, improving syndromes, pulmonary function and exercise capacity. But the
short- or long-term mechanism of them is not fully clear. Nuclear factor (NF)-κB/transforming growth factor
(TGF)-β1/smad2 signaling pathway is involved in the progress of inflammation and remodeling in chronic
obstructive pulmonary disease COPD. This study aimed to explore the long-term effects mechanism of Tiao-Bu Fei-Shen
granules by regulating NF-κB/TGF-β/Smads signaling in rats with COPD.
Methods: Sprague Dawley rats were randomized into control, model, Bufei Jianpi, Bufei Yishen, Yiqi Zishen and
aminophylline groups. COPD rats, induced by cigarette smoke and bacterial infections exposures, were administrated
intragastricly by normal saline, Bufei Jianpi, Bufei Yishen, Yiqi Zishen granules or aminophylline from week 9 through
20, respectively. At week 20 and 32, lung tissues were harvested. Immunohistochemistry was used to detect interleukin
(IL)-1β and tumor necrosis factor (TNF)-α, quantitative real-time polymerase chain reaction (qRT-PCR) was used for
TGF-β1 and Smad2 mRNA analysis, western blotting was used to determine the phosphorylation of NF-κB (p-NF-κB)
and IκBα (p-IκBα).
Results: COPD rats had marked airway injury, such as chronic airway inflammation and remodeling, emphysema,
which were improved in the three traditional Chinese medicines (TCM)-treated animals. The levels of IL-1β, TNF-α,
p-NF-κB, p-IκBα, TGF-β1 and Smad2 were significantly higher in COPD rats than in controls, while they were dramatically
reduced in the three TCM- and aminophylline-treated groups. At the meantime, all these endpoints were significantly
lower in three TCM-treated groups than in aminophylline group, especially in Bufei Jianpi and Bufei Yishen groups.
Compared to week 20, all endpoints decreased significantly in three TCM groups at week 32.
Conclusion: The three Tiao-Bu Fei-Shen therapies can reduce pulmonary inflammation and remodeling in COPD and
have significant long-term effects. NF-κB/TGF-β1/smad2 signaling might be involved in the mechanism.
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Chronic obstructive pulmonary disease (COPD), a pre-
valent smoking-related disease for which no disease-
altering therapies currently exist, is characterized by
persistent airflow limitation and progressive pathology that
resulted from recurrent inflammation and remodeling in
small airway. These pathological damages occur throughout
the course of COPD [1]. Nuclear factor (NF)-κB/trans-
forming growth factor (TGF)-β1/Smads2 signaling path-
way as an important pathway involved in inflammation
and remodeling is closely related to the progress of COPD.
NF-κB, a transcriptional activation protein, is widely
involved in various biological processes, such as inflam-
mation, oxidative stress, immune response, etc. The phos-
phorylation of NF-κB can initiate the gene transcriptions
and expressions of various cytokines, amplify the inflam-
matory response through a positive feedback cascade.
Additionally, NF-κB can also promote the expression of
TGF-β1 and activate TGF-β1/Smad2 signaling by binding
with NF-κB combining site locating in TGF-β1 activating
factor-tissue transglutaminase (tTG) gene promoter [2].
TGF-β1, an important proinflammatory cytokine with
strong fibrotic effect, plays a critical role in inflammatory
injury and repair as well as airway remodeling in COPD
by activating Smad2, a downstream receptor kinase of
TGF-β1 [3,4]. The effects of NF-κB/TGF-β/Smads path-
ways are as follows: 1) to promote the secretion of inflam-
matory cytokines and chemokines, augment inflammatory
response; 2) to induce fibroblast cell differentiation into
highly synthetic myofibroblasts and arguably transdiffe-
rentiation of epithelial cells into fibroblasts, produce more
cytokines to aggravate the lung injury; 3) to increase the
production of collagen fibers, elastic fibers and reticular
fibers, promote them deposit in the cell membrance,
which may lead to airway wall thickening and ultimately
aggravate airflow limitation; 4) to increase the secretion of
the extracellular matrix components (such as bronchopul-
monary tissue fibronectin, collagen type III and I glycopro-
tein, etc.) and finally result in airway plasticity decreasing
and remodeling [3-6].
COPD belongs to the category of lung distension
(FEIZHANG Disease) in traditional Chinese medicine
(TCM). In previous investigations, we found that the
patterns of lung-spleen qi (vital energy in life body) defi-
ciency, lung-kidney qi deficiency and lung-kidney qi-yin
(vital energy in life body and its material base, such
as blood, flesh, bones, etc.) deficiency were the most
common syndromes in the stable stage of COPD [7,8].
Accordingly, we formulated the three Tiao-Bu Fei-Shen
(Bufei Jianpi/invigorating the lung and strengthening the
spleen, Bufei Yishen/invigorating the lung and reinfor-
cing the kidney, Yiqi Zishen/replenishing qi and nourish-
ing the kidney) therapies and granules. In two previous
randomized controlled trials, we found that the threeTiao-Bu Fei-Shen granules can alleviate clinical symp-
toms in stable COPD patients, reduce frequency and
duration of acute exacerbation and improve pulmonary
function, exercise capacity and stamina and quality of life
[9]. In animal studies, it indicates that the three TCM
granules can reduce pulmonary and systemic inflamma-
tion, decrease collagen deposition and metalloproteinase
expression, reduce pathological impairment and improve
pulmonary function and have marked long-term effects
[10-12]. In this article, we aimed to explore the long-
term effects of the three Tiao-Bu Fei-Shen granules on
airway inflammation and remodeling by regulating NF-
κB/TGF-β1/Smads2 signaling in COPD rats.
Methods
Animals
Sixty male and sixty female two-month-old Sprague–
Dawley rats were purchased from Experimental Animal
Center of Henan province (Zhengzhou, China), weighing
180–220 g. All rats arrived at the animal facility of the la-
boratory seven days before the experiment were housed in
the individually ventilated cages (CA25, Fengshi, Suzhou,
China) and provided free access to sterile food and water.
Klebsiella pneumoniae
Klebsiella pneumoniae (strain ID: 46114) purchased
from National Center For Medical Culture Collection
(CMCC, Bejing, China) was cultured and prepared into
a suspension of 6 × 108 colony forming units (CFU) per
milliliter (mL) with normal saline before administered to
animals.
Preparation of COPD model
Experimental protocol was approved by the Experimen-
tal Animal Care and Ethics committees in the First Affil-
iated Hospital, Henan University of Traditional Chinese
Medicine, Zhengzhou, China.
Rats were randomized into control, model, Bufei Jianpi,
Bufei Yishen, Yiqi Zishen and aminophylline groups (10
male and 10 female rats in each group). COPD Rats
(except control ones) were exposed to tobacco (Hongqi
Canal® Filter tip cigarette, tobacco type, tar: 10 mg, nico-
tine content: 1.0 mg, carbon monoxide: 12 mg, Henan To-
bacco Industry, Zhengzhou, China) smoke of 8 cigarettes
per treatment, twice a day, during the first two weeks;
then fifteen cigarettes per treatment, three times a day,
from week 3 through week 12. The rats were placed in a
sealed box connected to smoke source to receive two or
three 30-minute exposures per day, with one or two three-
hour intervals. One hundred μL of Klebsiella pneumonia
suspension (6 × 108 CFU/mL) was slowly dropped into
nasal cavities in cigarette smoke-exposed rats, per 5 days,
from week 1 through 8 [13-17].
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At the end of week 8, two COPD rats were sacrificed
to validate whether the model were successfully made
or not according to the pathological changes of lung
tissue and pulmonary function impairment. The rest
rats were intragastrically administrated by normal
saline (2 mL per animal, in control and model rats),
Bufei Jianpi granule (4.84 g/kg/d, in Bufei Jianpi
group), Bufei Yishen granule (4.44 g/kg/d, in Bufei
Yishen group), Yiqi Zishen granule (4.84 g/kg/d, in
Yiqi Zishen group) and aminophylline (2.3 mg/kg/d, in
aminophylline group) from week 9 through 20, re-
spectively. Animal necropsies were executed at week
20 and 32.
The main components of the granules are as follows:
Bufei Jianpi granules (For lung-spleen qi deficiency syn-
drome): Huang Qi (Astragalus propinquus) 15 g, Dang
Shen (Codonopsis pilosula) 15 g, Bai Zhu (Atractylodes
macrocephala) 12 g, Fu Ling (Poria cocos) 12 g; Bufei
Yishen granules (For lung-kidney qi deficiency syndrome):
Ren Shen (Radix ginseng) 9 g, Huang Qi (Astragalus pro-
pinquus) 15 g, Shan Zhu Yu (Cornus officinalis) 12 g and
Yin Yang Huo (Herba epimedii) 9 g; Yiqi Zishen granule
(For lung-kidney qi and yin deficiency syndrome): Ren
Shen (Radix ginseng) 9 g, Huang Jing (Polygonatum king-
ianum) 15 g, Shu Di Huang (Radix rehmanniae praepar-
ata) 15 g, Mai Dong (Ophiopogon japonicus) 15 g and
Wu Wei Zi (Schisandra chinensis) 9 g. The herbs were
purchased from market and identified and prepared
into fluidextractum according to the standard operat-
ing procedure by the Department of Pharmaceutics in
the First Affiliated Hospital, Henan University of Trad-
itional Chinese Medicine, Zhengzhou, China. The hu-
man equivalent doses of the three TCM prescriptions
and aminophylline were calculated by the following
formula according references [9,10]. Drat = Dhuman × (Krat/
Khuman) × (Wrat/Whuman)
2/3 [18]. D: dose (mg/Kg); K: body
shape index; W: body weight.
Morphology
At week 20 and 32, lung tissues were sampled after
euthanasia and cut into 3-millimeter thick slices along
the maximum diameter of the right lower lobe and fixed
in 4% paraformaldehyde for 72 hours. The samples were
embedded with paraffin, 4 μm thick sections were cut
and stained with hematoxylin and eosin (H&E). All im-
ages were taken at amplification of 200 under an Olym-
pus PM-10 AD optical microscope and photographic
system (Olympus, Tokyo, Japan). Bronchia and lung
alveolar were observed under optical microscope and
bronchial wall thickness were measured by Image-Pro
Plus® (IPP) 6.0 software (Media Cybernetics, MD, USA).
Four bronchial wall thickness were measured in each
slice and averaged.Immunohistochemistry
The expressions of IL-1β and TNF-α in lung tissues
were analyzed by immunohistochemistry.
Paraffin-embedded lung tissue was sliced into 4 μm
thick slices, deparaffinized and blocked with 3% hydrogen
peroxide solution for 10 minutes to eliminate the activity
of endogenous peroxidase and then incubated in poly-
clonal anti-IL-1β and TNF-α antibody solution (1:100
dilution) overnight at 4°C, respectively. Subsequently
washed with phosphate buffer solution (PBS) three
times, the slices were incubated with horseradish peroxi-
dase (HRP)-labeled anti-mouse immunoglobulin G (IgG)
and counterstained with hematoxylin. In each section, five
random fields were photographed at a magnification of
400×. Semiquantitative evaluations were performed by
using IPP 6.0 software.
Quantitative real-time PCR analysis
The expressions of TGF-β1 and smad2 mRNAs of lung
tissues were analyzed by quantitative real-time PCR
(qRT-PCR).
Total RNA was extracted by using TRIzol reagent
(Life Technologies, NY, USA) according to the instruc-
tion and assessed by agarose gel electrophoresis and ab-
sorbance measurements at 260 and 280 nanometer (nm)
wavelength on SP-1901 ultraviolet light spectrophotom-
eter (Jinpeng Analytic Instrument Company, Shanghai,
China). Reverse transcription (RT) was proceeded by
using Supre® III First-Strand Synthesis Super Mix for
qRT-PCR Kit (Life Technologies, NY, USA), while PCR
was performed by using Platinum SYBR® Green® Super
Mix-UDG Kit (Life Technologies, NY, USA). The reac-
tion systems was prepared following the instructions of
the kits. The initial activation was at 95°C for 15 s, 60°C
for 15 s and 72°C for 30 s on an ABI 7300 real time
instrument (ABI, CA, USA).
The primers of TGF-β1 and smad2 were designed and
synthesized by Generay Biotech Co. Ltd. (Shanghai,
China) and sequences are as follows: TGF-β1, forward
(5′-3′): ATA GCA ACA ATT CCT GGC GTT ACC,
reverse (5′-3′): CAC TGA AGC GAA AGC CCT GTA
TTT; Smad2, forward (5′-3′): GCC GAG TGC CTA
AGT GAT CAG, reverse (5′-3′): TTA ACA GA C TGA
GCC AGA AGA GAG; glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH), forward (5′-3′): ACA GCA
ACA GGG TGG TGG AC, reverse (5′-3′): TTT GAG
GGT GCA GCG AAC TT.
Western blotting analysis
Lung tissues were homogenized in the cold homo-
genization buffer, containing 100 mM Tris, 150 mM
NaCl, 1% Triton-X, 0.1% sodium dodecy1 sulfate (SDS),
1 mmol/L ethylene diamine tetraacetic acid (EDTA),
1 mmol/L ethylene glycol tetraacetic acid (EGTA),
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tease and phosphatase inhibitors, then centrifuged at
4°C at 12000 g for 1 h. The concentrations of total
protein in the supernatant were detected by Bradford
method and then 2% SDS and 5% 2-mercaptoethanol
added before protein denaturalization at 95°C for
5 min. Fifty micrograms of protein was separated
by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred to poly-
vinylidene difluoride (PVDF) membranes (Millipore,
Bedfore, MA, USA). The membranes were blocked
with 2% BSA in Tris-buffered saline containing
20 mmol/L Tris-buffered saline (pH 7.4), 500 mmol/L
NaCl and 0.05% Tween 20, then incubated with
primary antibody, phosphorylation of nuclear factor
-κB (p-NF-κB), inhibitor of κBα (p-IκBα) or β-actin
(Santa Cruz, CA, USA) according to its instructions
and horseradish peroxidase (HRP)-conjugated secon-
dary antibodies (Santa Cruz, CA, USA). Finally, signals
were gained by using the Super ECL (enhanced chemi-
luminescence) Plus reagent (Solarbio, Shanghai, China)
and scanned and quantified by PowerLook 2100XL-USB
scanner (UMAX, Taiwan) and Image J software (NIH,
MD, USA).
Statistical analysis
Values are expressed as mean ± standard deviation (SD).
Statistical differences between groups were performed
by One-Way ANOVA with SPSS 19.0 software package
(SPSS, Chicago, IL, USA). Paired T test were used to
detect the difference between week 32 and 20 in each
group. The significance level is P < 0.05.Figure 1 Pathological changes in the lungs and bronchiole in rats tre
aminophylline at week 20 and 32 ( H&E stained). a = control, b = mod
1 = week 20; 2 = week 32. Amplification ×200.Results
Mortality
During the 32-week-period, two rats died in the model,
Bufei Jianpi, Bufei Yishen, Yiqi Zishen and aminophyl-
line groups respectively due to pulmonary abscess. One
control rat died due to foot abscess.
Histomorphology
As shown in Figure 1, marked bronchiole stenosis,
alveolar destruction, pulmonary bronchiole and arteriola
wall thickening were observed in COPD rats at week 20
and 32, whereas they were reduced in the three TCM-
and aminophylline-treated groups. No apparente impair-
ment was observed in control rats.
Bronchiole wall thickness
As shown in Figure 2, bronchiole wall thickness in the
model rats was 4-fold higher than that in control at both
week 20 and 32 (P < 0.01). It was significantly lower in
the three TCM- and aminophylline-treated group than
in model rats (P < 0.01), while the three TCM-treated
groups were significantly lower than aminophylline
group (P < 0.01), especially in Bu-Fei Jian-Pi and Bu-Fei
Yi-Shen groups (P < 0.01).
At week 32, bronchiole thickness in model group were
higher compared with that at week 20 (P < 0.05), while
the three TCM-treated groups were lower than those at
week 20 (P < 0.05, P < 0.01).
Cytokines
As shown in Figure 3, the levels of TNF-α and IL-1β in
the model group were significantly higher than those inated with Bufei Jianpi, Bufei Yishen, Yiqi Zishen granules or



















Figure 2 Bronchiole wall thickness in rats treated with Bufei Jianpi, Bufei Yishen, Yiqi Zishen granules or aminophylline at week 20
and 32. **P<0.01, vs model group; ##P<0.01, vs Bufei Jianpi group; ΔΔP<0.01, vs Bufei Yishen group; ▲▲P<0.01, vs Yiqi Zishen group; ○P<0.05,
○○P<0.01, vs Week 20 in the same group.
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while, they were much lower in the three TCM- and
aminophylline-treated group groups (all P < 0.01). The
three TCM-treatments showed much more benefit than
aminophylline (all P < 0.01), especially Bufei Jianpi and
Bufei Yishen granules.
At week 32, the expressions of TNF-α and IL-1β were
higher in model group than that at week 20 (P < 0.01),
while they were significantly lower in the three TCM-
treated groups (IL-1β, P < 0.05; TNF-α, P < 0.01).Phosphorylation of nuclear factor κB and inhibitor of κBα
At week 20 and 32, the p-NF-κB and p-IκBα were
significantly higher in model group than in control at
both week 20 and 32 (P < 0.01) and the three TCM- and
aminophylline-treated groups (P < 0.01) (Figure 4). In
addition, the expressions of the proteins were lower in
the three TCM-treated groups than aminophylline group
(P < 0.01), especially in Bufei Jianpi and Bufei Yishen
groups (P < 0.01).
At week 32, the phosphorylation levels of NF-κB and
IκBα were higher in model group than week 20 (P <
0.01 and P < 0.05, respectively), while they were signifi-
cantly lower in the three TCM-treated groups (P < 0.05
or P < 0.01).Expressions of TGF-β1 and Smad2 mRNA
At week 20 and 32, the expressions of TGF-β1 and
Smad2 mRNA were significantly higher in model group
than in control (P < 0.01) and the three TCM- and
aminophylline-treated groups (P < 0.01) (Figure 5). The
expressions of mRNAs were significantly lower in three
TCM-treated groups than aminophylline group (P <
0.01), especially in Bufei Jianpi and Bufei Yishen groups
(P < 0.01).
At week 32, the expressions of TGF-β1 and Smad2
mRNA were higher in model group compared to that at
-week 20 (P < 0.05, P < 0.01), conversely, they weresignificantly lower in three TCM-treated groups (P < 0.01,
P < 0.05).
Discussion and conclusions
The present study demonstrates that the three Tiao-Bu
Fei-Shen granules play distinctly suppressant roles on
inflammatory response and airway remodeling in COPD
rats induced by cigarette smoke exposures combined
with repeated bacterial infections via regulating NF-κB/
TGF-β1/Smad2 pathway.
The syndromes of lung-spleen qi deficiency, lung-
kidney qi deficiency and lung-kidney qi-yin deficiency
are the most common syndromes in stable COPD. Bufei
Jianpi, Bufei Yishen and Yiqi Zishen therapies and gran-
ules are the corresponding rules and medicines of treat-
ments [7,8]. Previously completed multicenter clinical
trials had shown that Bufei Jianpi, Bufei Yishen and Yiqi
Zishen granules can improve pulmonary function, re-
duce the incidence and duration of acute exacerbation,
improve patients’ quality of life, have beneficial long-
term effects after a 12-month follow-up [9]. Therefore,
this study aimed to evaluate the long-term effects of
Bufei Jianpi, Bufei Yishen and Yiqi Zishen granules on
pulmonary inflammation, airway remodeling and explore
the role of NF-κB/TGF-β1/Smad2 signaling pathway on
COPD rats.
Airway remodeling and airflow obstruction, resulted
from chronic inflammation occurring in the central and
peripheral airways as well as lung parenchyma, play
important roles in the development of COPD [1,19,20].
NF-κB and TGF-β/Smads signaling pathways are the
most important two paths involved in the course of
inflammation and remodeling. NF-κB, a pivotal transcrip-
tion factor of the inflammatory response, can be activated
by numerous stimuli and participate in the regulation of
hundreds of genes by binding to discrete DNA sequences,
known as κB elements, in gene promoters and enhancers,
such as TGF-β, TNF-α, IL-1β, etc. [21,22]. The expres-

















Figure 3 (See legend on next page.)
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Figure 3 Levels of TNF-α (A) and IL-1β (B) in the lungs in rats treated with Bufei Jianpi, Bufei Yishen, Yiqi Zishen granules or
aminophylline at week 20 and 32. a = control, b = model; c = Bufei Jianpi; d= Bufei Yishen; e = Yiqi Zishen; f = aminophylline. **P<0.01, vs


















Figure 4 Phosphorylation of NF-κB and IκBα of lung in rats treated with Bufei Jianpi, Bufei Yishen, Yiqi Zishen granules or
aminophylline at week 20 and 32. a = control, b = model; c = Bufei Jianpi; d= Bufei Yishen; e = Yiqi Zishen; f = aminophylline. **P<0.01, vs
model group; ##P<0.01, vs Bufei Jianpi group; ΔΔP<0.01, vs Bufei Yishen group; ▲▲P<0.01, vs Yiqi Zishen group; ○P<0.05, ○○P<0.01, vs Week 20 in
the same group.




















Figure 5 Expressions of TGF-β1 (A) and Smad2 (B) mRNA in rats treated with Bufei Jianpi, Bufei Yishen, Yiqi Zishen granules or
aminophylline at week 20 and 32. **P<0.01, vs model group; ##P<0.01, vs Bufei Jianpi group; ΔΔP<0.01, vs Bufei Yishen group; ▲▲P<0.01, vs Yiqi
Zishen group; ○P<0.05, ○○P<0.01, vs Week 20 in the same group.
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ficantly compare with normal control subjects. IL-6, a
downstream cytokine of NF-κB pathways, increased along
with NF-κB [23]. Decreasing of phosphorylation of NF-κB
can decrease the levels of downstream cytokines, reduce
the inflammatory response in lungs of COPD, improve
pulmonary function and finally reduce the incidences of
acute exacerbation [21].
TGF-β1, a multipotential cytokine with strong fibro-
genic effect, is presented in many tissues and cells in
human body and is the most abundant isoform in the
superfamily of transforming growth factors and with
both structural and inflammatory cells being sources of
TGF-β1 in the lungs [3]. In addition, TGF-β receptors
are suggested to play a significant role in the pathogen-
esis of COPD through their regulation of TGF-β/Smads
pathways. A previous study suggests that pharmacologic
inhibition of TGF-β signaling can protect the murine
lung from altered lung histology, impaired lung function
and a panel of injury measures that accompany cigarette
smoke-induced COPD [5].
There are strong interactions between NF-κB and TGF-
β/Smads signaling to form NF-κB/TGF-β/Smads pathway
as TGF-β can be administrated by NF-κB signaling path-
way. NF-κB/TGF-β/Smads pathway leads on a global stage
in airway inflammation and remodeling in COPD.
In this study, we have found that phosphorylation
levels of NF-κB and IκBα, mRNA expressions of TGF-β1
and Smad2 increased significantly in the lungs of COPDrats. Bufei Jianpi, Bufei Yishen and Yiqi Zishen granules
can reduce the phosphorylation of NF-κB and IκBα pro-
teins and depress TGF-β1 and Smad2 mRNA expres-
sions at both week 20 and 32. It indicates that the three
Tiao-Bu Fei-Shen granules have a dramatic short- and
long-term effect on reducing pulmonary pathological
impairment and inflammatory responses, improving air-
way remodeling via regulating NF-κB/TGF-β1/Smad2
signaling. However, as the three traditional Chinese
medicine prescriptions are very complicated compounds,
it need more further study to determine what the exactly
constituents make it work.Competing interests
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